Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Issue 1 (8th October 2013)

• Record Type: Journal Article
• Authors: Halabi, Susan; Rini, Brian; Escudier, Bernard; Stadler, Walter M.; Small, Eric J.
• Is Part Of: Cancer. Volume 120:Issue 1(2014)
• Page Start: 52
• Page End: 60
• Publication Date: 2013-10-08
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28221
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28221-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>The current study was conducted to investigate the dependence between progression‐free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediate endpoint of OS in this patient population.</p> </sec> <sec id="cncr28221-sec-0002" sec-type="section"> <title>METHODS</title> <p>A total of 1381 patients from 2 prospective phase 3 trials (Cancer and Leukemia Group B [CALGB] 90206 and AVOREN) of interferon‐alpha with or without bevacizumab were analyzed. Both trials recruited previously untreated patients with clear cell mRCC with an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow, hepatic, cardiac, and renal function; and controlled blood pressure. The CALGB study served as the training data set, and the AVOREN study served as the testing data set. The dependence between PFS and OS was investigated using the Kendall tau for bivariate time‐to‐event endpoints.</p> </sec> <sec id="cncr28221-sec-0003" sec-type="section"> <title>RESULTS</title> <p>In the training data set, the median OS times among patients who experienced progressive disease at 3 months or 6 months were 6 months and 8 months, respectively, compared with 25 months and 30 months, respectively, (<italic>P</italic> < .001) in patients who did not develop disease progress. The adjusted hazard ratios (HR) were 2.6 (<italic>P</italic> < .0001) and 2.8 (<italic>P</italic> < .0001), respectively, for patients who did and did not progress at 3 months or 6 months. The dependence between PFS and OS was 0.53. These associations were confirmed in the testing data set.</p> </sec> <sec id="cncr28221-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>In patients with mRCC who were treated with interferon‐alpha with or without bevacizumab, the PFS at 3 months and 6 months was found to be predictive of OS. A high dependence between PFS and OS was observed, suggesting that PFS may be used as a surrogate endpoint for OS. Although this is a novel observation for RCC, these findings require validation in patients with mRCC who are treated with other targeted agents. <bold><italic>Cancer</italic> 2014;120:52–60</bold>. © <italic>2013 American Cancer Society</italic>.</p> </sec> </abstract>